Friday, March 13, 2026
21.3
C
Bengaluru
Hot topics
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Biocon Bats for Affordable Insulin and Ozempic
🩺 Insulin, Innovation, and Independence: How Biocon, Civica, and...
Uniform Code for Pharmaceutical Marketing Practices: 2011 and Now
In September 2011, MedicinMan published a UCPMP Special Issue...
First Approach in Pharma
Independence Day Special issue with Vivek Hattangadi tracing the India pharma brand story from before Independence till today.
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
Hot topics
Customer Engagement and Experience are the New Differentiators
At the IDMA Marketing and Sales Conference in Mumbai...
Pharma GCCs in India — Hype, Reality & What’s Next?
Part 1: Pharma GCCs in India — Orange Markets...
Healthcare Marketing in the Covid-19 Era
How should healthcare business leaders (pharma, devices, diagnostics, disposables...
Alok Sonig Appointed CEO of Rosemont Pharmaceuticals
Effective January 1, 2026, Rosemont Pharmaceuticals has announced the...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The Antifungal Blind Spot: India’s Quiet Clinical Crisis
A market analysis and clinical commentary on the growing...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
Newsletter
Get important news delivered directly to your inbox and stay connected!